Skip to main content
letter
. 2020 Nov 1;202(9):1304–1308. doi: 10.1164/rccm.202007-2778LE

Table 1.

Demographic, Clinical, and Laboratory Parameters in the Treated Patients

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Demographics          
 Sex M F M F M
 Age, yr 56 40 46 51 74
Past medical history Esophagitis, psoriasis, allergic rhinitis, and hypogonadism Type 2 diabetes, depression, posttraumatic stress disorder, and morbid obesity Lambert Eaton syndrome, glaucoma, type 2 diabetes, and penile carcinoma in situ Asthma Hypertension; awaiting surgery for a benign posterior fossa tumor (on dexamethasone)
Prehospital symptomatic period, d 8 5 10 7 9
Time from hospital admission to LFG316 administration, d 34 7 22 12 11
Inpatient course, before LFG316 4 d of mechanical ventilation on ICU early in COVID-19 course before ward discharge for 14 d, then ICU readmission Rapid escalation to critical care within 48 h of hospital admission Rapid escalation to critical care within 12 h of hospital admission Admitted to critical care Day 3 after hospital admission with severe respiratory failure Admission to critical care 1 d after hospital admission with severe hypoxia
ICU course          
 Predrug steroids, g* 3.75 0.3 0 0.45 0.48
 Ventilation duration before LFG316, d 4 plus 12 5 22 9 11
 High-frequency oscillatory ventilation No Yes Yes No No
 Nitric oxide Yes Yes No No No
 ECMO referral No Yes No No No
 Prone Yes Yes Yes Yes Yes
 Paralysis Yes Yes Yes Yes Yes
 Pulmonary emboli Yes No No No Yes
  Normal Range Patient 1
 Patient 2
 Patient 3
 Patient 4
 Patient 5
Before Dosing First 48 h Day 7–10 Before Dosing First 48 h Day 7–10 Before Dosing First 48 h Day 7–10 Before Dosing First 48 h Day 7–10 Before Dosing First 48 h Day 5–8
Hemoglobin, g/L 130–180 90.0 92.0 90.0 90.0 102 96.0 90.0 78.0 73.0 90 91.0 113 114 116 98.0
Platelets, ×109/L 150–400 305 342 371 99 480 428 99 75 35 241 227 358 339 324 393
Neutrophils, ×109/L 1.7–7.5 7.5 8.2 10.4 17.4 26.2 10.5 17.4 9.9 4.6 5.2 6.3 3.5 7.5 7.3 8.0
Lymphocytes, ×109/L 1.0–4.5 1.5 1.1 1.6 0.9 3.0 1.4 0.9 0.4 0.1 1.0 1.2 1.7 1.3 1.0 1.9
                                 
Prothrombin time, s 9.0–13.0 13.0 11.7 — 12.3 13.0 13.0 11.4 — 12.1 12.9 12.6 — 13.0 12.5 13.5
Activated partial thromboplastin time, s 23.0–38.0 37.8 39.2 — 28.6 30.9 34.2 33.5 — 29.2 29.3 32.0 — 30.9 33.0 34.5
Fibrinogen, g/L 2.0–4.0 6.3 6.0 — 8.5 6.0 7.2 5.4 — 4.0 11.3 7.7 — 8.8 7.7 10.0
C3, g/L 0.75–1.65 2.13 1.86 2.03 1.80 1.67 1.93 1.12 1.17 1.22 1.54 1.73 2.02 1.49 1.36 2.00
C4, g/L 0.14–0.54 0.45 0.43 0.45 0.30 0.28 0.40 0.27 0.30 0.32 0.24 0.30 0.36 0.10 0.15 0.21
C5, mg/L 80.5–86.2 76.9 75.2 93.4 71.3 80.4 94.7 86.5 76.1 78.9 103.5 94.8 92.9 — — —
C5a, μg/L 8.8–22.3 119.1 28.6 16.8 36.1 22.1 15.6 28.0 16.8 18.6 31.4 22.0 26.5 — — —
Terminal complement complex, mg/L 1.2–7.2 17.3 6.5 3.3 13.1 3.2 8.6 10.3 3.8 5.3 11.3 5.5 12.9 12.4 2.1 7.6
Classical pathway hemolytic activity (CH50), hemolytic units 70–130 229.8 0 175.1 132.2 0 69.9 284.4 0 88.9 268.4 0 105.5 247.9 0 151.5
C-reactive protein, mg/L <5 99 31 8 170 36 59 113 22 24 164 43 27 133 182 149
Ferritin, μg/L 15–300 666 599 354 350 266 169 3,004 — 384 473 248 — 424 421 508
Lactate dehydrogenase, U/L 125–200 478 329 469 500 533 370 571 — 287 306 241 — 313 315 326
Procalcitonin, μg/L <0.05 0.14 0.08 0.05 0.57 0.27 0.20 3.27 3.09 1.01 0.08 0.05 — 1.32 0.48 0.66
Troponin I (high sensitivity), ng/L                                
 Male 0–34 23 13 12 — — — 89 — 46 — — — 9 20 44
 Female 0–16 — — — <2 <2 3 — — — 2 <2 — — — —
Follow-up duration, days since admission (after LFG316)† — 81 (48)
 50 (43)
 63 (42)
 49 (38)
 20 (8)
Current care level‡ 1–6 1 1 3 1 6

Definition of abbreviations: COVID-19 = coronavirus disease; ECMO = extracorporeal membrane oxygenation.

*

Steroids, total prednisolone equivalent dose given in the Critical Care Unit before administration of LFG316; in a comparator group of 28 clinically matched patients, steroid dose was 0.95 g (SD, 0.27 g).

†

Correct at date of original submission, June 12, 2020; censored at Day 20 after admission for patient 5.

‡

Care level at date of submission defined by six-point scale consisting of the following categories: 1 = not hospitalized; 2 = hospitalized, not requiring supplemental oxygen; 3 = hospitalized, requiring supplemental oxygen; 4 = hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 5 = hospitalized, requiring invasive mechanical ventilation, ECMO, or both; 6 = death.